Related Experiment Videos
Surrogate markers in HIV disease
1Nuffield Department of Clinical Medicine, John Radcliffe Hospital, Headington, Oxford, UK.
The Journal of Antimicrobial Chemotherapy
|May 1, 1996
Summary
Surrogate markers like CD4 counts can speed up HIV treatment assessment but don't reliably predict long-term outcomes. More validation is needed before using them for clinical efficacy conclusions.
Area of Science:
- Virology
- Immunology
- Clinical Pharmacology
Background:
- Surrogate markers offer a faster way to evaluate HIV treatments compared to clinical endpoints.
- Assessing ideal surrogate marker characteristics and potential drug class extrapolation dangers is crucial.
Purpose of the Study:
- To compare CD4 lymphocyte counts as a surrogate marker against clinical endpoints in HIV treatment.
- To evaluate the correlation between CD4 count changes and AIDS progression/survival rates.
Main Methods:
- Analysis of 14 randomized controlled trials involving nucleoside analogue treatments for HIV.
- Comparison of CD4 count changes with rates of AIDS progression and survival.
Main Results:
- A moderate correlation was observed between CD4 count changes and AIDS development, especially in short-term trials.
- Little correlation was found between CD4 counts and overall patient survival.
- Studies comparing clinical endpoints with plasma viremia measures are pending.
Conclusions:
- Currently, no surrogate marker has been definitively proven to predict anti-HIV treatment efficacy.
- Surrogate markers should be used for initial drug screening, not for definitive clinical efficacy conclusions, until validated by long-term trials.